학술논문
Response to 'Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’'
Document Type
article
Source
Dermatology and Therapy, Vol 14, Iss 3, Pp 823-827 (2024)
Subject
Language
English
ISSN
2193-8210
2190-9172
2190-9172